help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baertschi, A. J.
Right arrow Articles by Friedli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baertschi, A. J.
Right arrow Articles by Friedli, M.

Endocrinology, Vol 116, 499-502, Copyright © 1985 by Endocrine Society


ARTICLES

A novel type of vasopressin receptor on anterior pituitary corticotrophs?

AJ Baertschi and M Friedli

Suspensions of rat anterior pituitary cells were exposed to corticotropin-releasing factor (CRF) (5 nM) and various neurohormones (0.002-1000 nM). CRF-induced secretion of ACTH was doubled by 0.1 nM arginine vasopressin (AVP), 0.2 nM arginine vasotocin, 1 nM oxytocin, 10 nM angiotensin II, and 100 nM noradrenalin; vasoactive intestinal peptide had no effect at 0.2-200 nM. CRF potentiation by AVP was also observed at lower concentrations of CRF. Since AVP appeared to be the most potent modulator of CRF-induced ACTH secretion, potentiation was further tested with specific antidiuretic and oxytocic agonists. Potentiation was clearly related to pressor biological activity, less so to antidiuretic, and hardly at all to oxytocic activities. However, even at 200 nM, the antipressor antagonists dPTyr(Me)AVP and d(CH2)5Tyr(Me)AVP had no effect on potentiation by AVP. The lack of antagonism was partly due to the agonistic effects of the antagonists on the pituitary gland, an effect not observed within vascular tissue. The results thus suggest that anterior pituitary vasopressin receptors resemble, but are not identical to, V1 (pressor and hepatic), do not resemble the V2 (renal), and might be classified as V3 (pituitary) receptors.


This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
M. V. Mikhailova, P. R. Mayeux, A. Jurkevich, W. J. Kuenzel, F. Madison, A. Periasamy, Y. Chen, and L. E. Cornett
Heterooligomerization between Vasotocin and Corticotropin-Releasing Hormone (CRH) Receptors Augments CRH-Stimulated 3',5'-Cyclic Adenosine Monophosphate Production
Mol. Endocrinol., September 1, 2007; 21(9): 2178 - 2188.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
H. Orcel, V. A. Tobin, G. Alonso, and A. Rabie
Immunocytochemical Localization of Vasopressin V1a Receptors in the Rat Pituitary Gonadotropes
Endocrinology, November 1, 2002; 143(11): 4385 - 4388.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
F. A. Laszlo, C. Varga, I. Pavo, J. Gardi, M. Vecsernyes, M. Galfi, E. Morschl, F. Laszlo, and G. B. Makara
Vasopressin pressor receptor-mediated activation of HPA axis by acute ethanol stress in rats
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2001; 280(2): R458 - R465.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Moro, P. Putignano, M. Losa, C. Invitti, C. Maraschini, and F. Cavagnini
The Desmopressin Test in the Differential Diagnosis between Cushing's Disease and Pseudo-Cushing States
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3569 - 3574.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
D. Engler, E. Redei, and I. Kola
The Corticotropin-Release Inhibitory Factor Hypothesis: A Review of the Evidence for the Existence of Inhibitory as Well as Stimulatory Hypophysiotropic Regulation of Adrenocorticotropin Secretion and Biosynthesis
Endocr. Rev., August 1, 1999; 20(4): 460 - 500.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
P. L. M. Dahia and A. B. Grossman
The Molecular Pathogenesis of Corticotroph Tumors
Endocr. Rev., April 1, 1999; 20(2): 136 - 155.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
M. Thibonnier, J. A. Preston, N. Dulin, P. L. Wilkins, L. N. Berti-Mattera, and R. Mattera
The Human V3 Pituitary Vasopressin Receptor: Ligand Binding Profile and Density-Dependent Signaling Pathways
Endocrinology, October 1, 1997; 138(10): 4109 - 4122.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Abel, N. Wittau, T. Wieland, G. Schultz, and F. Kalkbrenner
Cell Cycle-dependent Coupling of the Vasopressin V1a Receptor to Different G Proteins
J. Biol. Chem., October 13, 2000; 275(42): 32543 - 32551.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society